DORIS definition of remission in SLE: final recommendations from an international task force

Autor: van Vollenhoven RF, Bertsias, G, Doria, A, Isenberg, D, Morand, E, Petri, Ma, Pons-Estel, Ba, Rahman, A, Ugarte-Gil, Mf, Voskuyl, A, Arnaud, L, Bruce, In, Cervera, R, Costedoat-Chalumeau, N, Gordon, C, Houssiau, Fa, Mosca, M, Schneider, M, Ward, Mm, Alarcon, G, Aringer, M, Askenase, A, Bae, Sc, Bootsma, H, Boumpas, Dt, Brunner, H, Clarke, Ae, Coney, C, Czirják, L, Dörner, T, Faria, R, Fischer, R, Fritsch-Stork, R, Inanc, M, Jacobsen, S, Jayne, D, Kuhn, A, van Leeuw, B, Limper, M, Mariette, X, Navarra, S, Nikpour, M, Olesinska, Mh, Pons-Estel, G, Romero-Diaz, J, Rubio, B, Schoenfeld, Y, Bonfá, E, Smolen, J, Teng, Yko, Tincani, A, Tsang-A-Sjoe, M, Vasconcelos, C, Voss, A, Werth, Vp, Zakharhova, E, Aranow, C

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3728::cb87797d329471603abbeb5b72dc0acb
http://hdl.handle.net/11568/1113156

Targeted therapies in rheumatoid arthritis: Focus on rituximab

Autor: Teng, YKO, Huizinga, TWJ, van Laar, JM

Publikováno v: Biologics : Targets & Therapy

B-cell depletion is a new strategy for treating patients with rheumatoid arthritis (RA). In the past years, several studies have proven the efficacy of anti-CD20 mediated B-cell depletion with rituximab (Mabthera((R))) in RA patients who failed TNF-b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::d13418204118330cef991ded12d1f435
http://europepmc.org/articles/PMC2721296

Circulating levels of endogenous complement inhibitors correlate inversely with complement consumption in systemic lupus erythematosus.

Autor: van der Meulen S; Department of Immunology, Leiden University Medical Center, Leiden, the Netherlands., Monahan RC; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands., Gelderman KA; Sanquin Diagnostic Services, Amsterdam, the Netherlands., van Kooten C; Department of Internal Medicine section Nephrology, Center of Expertise for Lupus-, Vasculitis and Complement-mediated Systemic Autoimmune Diseases, Leiden University Medical Center, Leiden, the Netherlands., Teng YKO; Department of Internal Medicine section Nephrology, Center of Expertise for Lupus-, Vasculitis and Complement-mediated Systemic Autoimmune Diseases, Leiden University Medical Center, Leiden, the Netherlands., Huizinga TWJ; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands., Steup-Beekman GM; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands.; Department of Rheumatology, Haaglanden Medical Center, The Hague, the Netherlands., Trouw LA; Department of Immunology, Leiden University Medical Center, Leiden, the Netherlands.

Publikováno v: European journal of immunology [Eur J Immunol] 2024 Nov; Vol. 54 (11), pp. e2450998. Date of Electronic Publication: 2024 Aug 20.

Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus.

Autor: Arends EJ; Expert Center for Lupus-, Vasculitis-, and Complement-Mediated Systemic diseases (LuVaCs), Department of Internal Medicine-Section Nephrology, Leiden University Medical Centre, Leiden, The Netherlands., Zlei M; Department of Immunology, Leiden University Medical Centre, Leiden, The Netherlands.; Medical Laboratory, Department of Flow Cytometry, Regional Institute of Oncology, Iasi, Romania., Tipton CM; Lowance Centre for Human Immunology, Emory University School of Medicine, Atlanta, GA, USA.; Department of Medicine, Division of Rheumatology, Emory University, Atlanta, GA, USA., Cotic J; Clinical Statistics, GSK, Middlesex, UK., Osmani Z; Expert Center for Lupus-, Vasculitis-, and Complement-Mediated Systemic diseases (LuVaCs), Department of Internal Medicine-Section Nephrology, Leiden University Medical Centre, Leiden, The Netherlands., de Bie FJ; Department of Immunology, Leiden University Medical Centre, Leiden, The Netherlands., Kamerling SWA; Expert Center for Lupus-, Vasculitis-, and Complement-Mediated Systemic diseases (LuVaCs), Department of Internal Medicine-Section Nephrology, Leiden University Medical Centre, Leiden, The Netherlands., van Maurik A; Clinical Pharmacology and Experimental Medicine, GSK, Hertfordshire, UK., Dimelow R; Clinical Pharmacology Modelling and Simulation, GSK, Hertfordshire, UK., Gregan YI; Clinical Science Immunology, GSK, Collegeville, PA, USA., Fox NL; Clinical Development, GSK, Collegeville, PA, USA., Rabelink TJ; Expert Center for Lupus-, Vasculitis-, and Complement-Mediated Systemic diseases (LuVaCs), Department of Internal Medicine-Section Nephrology, Leiden University Medical Centre, Leiden, The Netherlands., Roth DA; Research and Development, GSK, Collegeville, PA, USA., Sanz I; Lowance Centre for Human Immunology, Emory University School of Medicine, Atlanta, GA, USA., van Dongen JJM; Centro de Investigación del Cáncer-Instituto de Biología Molecular y Celular del Cáncer (CIC-IBMCC, USAL-CSIC-FICUS) and Department of Medicine, University of Salamanca, Salamanca, Spain., van Kooten C; Expert Center for Lupus-, Vasculitis-, and Complement-Mediated Systemic diseases (LuVaCs), Department of Internal Medicine-Section Nephrology, Leiden University Medical Centre, Leiden, The Netherlands., Teng YKO; Expert Center for Lupus-, Vasculitis-, and Complement-Mediated Systemic diseases (LuVaCs), Department of Internal Medicine-Section Nephrology, Leiden University Medical Centre, Leiden, The Netherlands.

Publikováno v: Rheumatology (Oxford, England) [Rheumatology (Oxford)] 2024 Sep 01; Vol. 63 (9), pp. 2387-2398.

Immunosuppression Withdrawal in Patients with Lupus Nephritis: When, How, and for Whom Will It Be Safe?

Autor: Frangou E; Department of Nephrology, Limassol General Hospital, State Health Services Organization, Limassol, Cyprus.; Department of Basic and Clinical Sciences, University of Nicosia Medical School, Nicosia, Cyprus., Anders HJ; Division of Nephrology, Department of Internal Medicine IV, Hospital of the Ludwig-Maximilians-University, Munich, Germany., Bajema IM; Department of Pathology and Medical Biology, University of Groningen, University Medical Center, Groningen, The Netherlands., Teng YKO; Center of Expertise for Lupus, Vasculitis and Complement-mediated Systemic Disease (LuVaCs), Department of Internal Medicine - Section Nephrology, Leiden University Medical Center, Leiden, The Netherlands.; Department of Nephrology, Leiden University Medical Center, Leiden, The Netherlands., Malvar A; Nephrology Unit, Hospital Fernandez, Buenos Aires, Argentina., Rovin BH; Division of Nephrology, The Ohio State University Wexner Medical Center, Columbus, Ohio., Kronbichler A; Department of Internal Medicine IV, Nephrology and Hypertension, Medical University Innsbruck, Innsbruck, Austria.

Publikováno v: Journal of the American Society of Nephrology : JASN [J Am Soc Nephrol] 2024 Jul 01; Vol. 35 (7), pp. 955-958. Date of Electronic Publication: 2024 Apr 09.